 |
| Sjogren’s Syndrome Market |
Sjogren's syndrome is an autoimmune disease that causes dryness in the mouth and eyes due to a decrease in tear and saliva production. Pharmaceutical products such as anti-inflammatory, immunosuppressants drugs, and artificial tears and saliva substitutes are predominantly used for managing the symptoms associated with Sjogren's syndrome. The global Sjogren's Syndrome Market is estimated to be valued at US$ 2.1 billion in 2023 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023-2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Growth Accelerated by Innovative Drugs
Research and development activities have allowed pharmaceutical companies to
develop innovative drugs that target specific molecules and pathways involved
in the pathogenesis of Sjogren's syndrome. For instance, in 2021, Roche
received FDA approval for its drug phenofibrate for the treatment of Sjogren's
syndrome. Phenofibrate functions by activating peroxisome
proliferator-activated receptor alpha (PPAR-α) to reduce inflammation in
affected tissues. Similarly, other companies are evaluating drugs such as
belimumab, gimsilumab, and lenabasum in clinical trials, which if approved, can
boost the market growth exponentially over the forecast period.
Segment
Analysis
The global Sjogren's Syndrome market is dominated by the diagnostic segment
which holds the largest market share currently. This is because of the high use
of tests like salivary gland biopsy, lip biopsy, Schirmer's test for diagnosing
Sjogren's Syndrome in patients showing early symptoms. The treatment segment is
expected to witness higher growth during the forecast period due to
introduction of new drugs for effective management of the disease.
Key Takeaways
The global Sjogren's
Syndrome Market Growth is expected to witness high growth over the
forecast period of 2022-2030.
Regional analysis: North America represents the largest market currently owing
to increasing prevalence of Sjogren's Syndrome.Asia Pacific is poised to grow
at the fastest pace during the forecast years due to rising patient awareness
levels regarding early disease diagnosis & treatment availability across
major countries.
Key players: Key players operating in the Sjogren's Syndrome market are
Hoffmann-La Roche Ltd, Pfizer, Mallinckrodt, Novartis, Inova Diagnostics, Inc,
AstraZeneca, Amgen, and AbbVie.
For more insights, read- https://www.ukwebwire.com/sjogrens-syndrome-market-trends-size-and-share-analysis/
For more details on the report, Read- https://cmiinfopiece.blogspot.com/2024/01/the-global-luxury-travel-market-growth.html
0 Comments